Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy: Insights from the NEFIGAN trial

David Wimbury; Masahiro Muto; Jasraj S. Bhachu; Katrin Scionti; Jeremy Brown; Karen Molyneux; Claudia Seikrit; Dita Maixnerová; Laura Pérez-Alós; Peter Garred; Jürgen Floege; Vladimír Tesař; Bengt Fellstrom; Rosanna Coppo; Jonathan Barratt

doi:10.1016/j.kint.2023.11.003

Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy: Insights from the NEFIGAN trial

David Wimbury, Masahiro Muto, Jasraj S. Bhachu, Katrin Scionti, Jeremy Brown, Karen Molyneux, Claudia Seikrit, Dita Maixnerová, Laura Pérez-Alós, Peter Garred, Jürgen Floege, Vladimír Tesař, Bengt Fellstrom, Rosanna Coppo, Jonathan Barratt^*

^*Corresponding author af dette arbejde

Afdeling for Klinisk Immunologi

22 Citationer (Scopus)

Originalsprog	Engelsk
Tidsskrift	Kidney International
Vol/bind	105
Udgave nummer	2
Sider (fra-til)	381-388
Antal sider	8
ISSN	0085-2538
DOI	https://doi.org/10.1016/j.kint.2023.11.003
Status	Udgivet - 2024

Adgang til dokumentet

10.1016/j.kint.2023.11.003

Andre filer og links

Link to publication in Scopus

Citationsformater

Wimbury, D., Muto, M., Bhachu, J. S., Scionti, K., Brown, J., Molyneux, K., Seikrit, C., Maixnerová, D., Pérez-Alós, L., Garred, P., Floege, J., Tesař, V., Fellstrom, B., Coppo, R., & Barratt, J. (2024). Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy: Insights from the NEFIGAN trial. Kidney International, 105(2), 381-388. https://doi.org/10.1016/j.kint.2023.11.003

Wimbury, D, Muto, M, Bhachu, JS, Scionti, K, Brown, J, Molyneux, K, Seikrit, C, Maixnerová, D, Pérez-Alós, L, Garred, P, Floege, J, Tesař, V, Fellstrom, B, Coppo, R & Barratt, J 2024, 'Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy: Insights from the NEFIGAN trial', Kidney International, bind 105, nr. 2, s. 381-388. https://doi.org/10.1016/j.kint.2023.11.003

@article{130b76a14cf14550aa5c9c12ab5d9aa9,

title = "Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy: Insights from the NEFIGAN trial",

keywords = "chronic kidney disease, complement, cytokines, glomerulus, IgA nephropathy, proteinuria, Glomerulonephritis, IGA/diagnosis, Proteinuria/pathology, Humans, Immunoglobulin A, Kidney Glomerulus/pathology, Biomarkers, Budesonide/adverse effects",

author = "David Wimbury and Masahiro Muto and Bhachu, {Jasraj S.} and Katrin Scionti and Jeremy Brown and Karen Molyneux and Claudia Seikrit and Dita Maixnerov{\'a} and Laura P{\'e}rez-Al{\'o}s and Peter Garred and J{\"u}rgen Floege and Vladim{\'i}r Tesa{\v r} and Bengt Fellstrom and Rosanna Coppo and Jonathan Barratt",

year = "2024",

doi = "10.1016/j.kint.2023.11.003",

language = "English",

volume = "105",

pages = "381--388",

journal = "Kidney International",

issn = "0085-2538",

publisher = "Elsevier BV",

number = "2",

}

TY - JOUR

T1 - Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy

T2 - Insights from the NEFIGAN trial

AU - Wimbury, David

AU - Muto, Masahiro

AU - Bhachu, Jasraj S.

AU - Scionti, Katrin

AU - Brown, Jeremy

AU - Molyneux, Karen

AU - Seikrit, Claudia

AU - Maixnerová, Dita

AU - Pérez-Alós, Laura

AU - Garred, Peter

AU - Floege, Jürgen

AU - Tesař, Vladimír

AU - Fellstrom, Bengt

AU - Coppo, Rosanna

AU - Barratt, Jonathan

PY - 2024

Y1 - 2024

KW - chronic kidney disease

KW - complement

KW - cytokines

KW - glomerulus

KW - IgA nephropathy

KW - proteinuria

KW - Glomerulonephritis, IGA/diagnosis

KW - Proteinuria/pathology

KW - Humans

KW - Immunoglobulin A

KW - Kidney Glomerulus/pathology

KW - Biomarkers

KW - Budesonide/adverse effects

UR - http://www.scopus.com/inward/record.url?scp=85180588423&partnerID=8YFLogxK

U2 - 10.1016/j.kint.2023.11.003

DO - 10.1016/j.kint.2023.11.003

M3 - Letter

C2 - 38008160

SN - 0085-2538

VL - 105

SP - 381

EP - 388

JO - Kidney International

JF - Kidney International

IS - 2

ER -